文献速递乳腺外科

微创活检诊断乳腺癌新辅助治疗后病理完全缓解

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
PubMed 文献 · Ann Surg · 2022-01-01

这项多中心前瞻性试验纳入452例新辅助全身治疗(NST)后影像学确认部分或完全缓解的1-3期乳腺癌患者,398例纳入全分析,评估影像引导真空辅助活检(VAB)诊断乳腺病理完全缓解(pCR-B)的可靠性。VAB单独诊断的假阴性率(FNR)为17.8%,探索性分析显示7G最大针具VAB无假阴性,影像联合VAB可将FNR降至6.2%。

要点

  • 影像引导VAB单独诊断pCR-B的假阴性率为17.8%,高于预期。
  • 7G最大针具VAB未出现假阴性结果。
  • 影像联合VAB可将假阴性率降至6.2%。

核心结论

  • 影像引导VAB遗漏残留病变的频率高于预期,在免除乳腺手术前需改进操作与患者选择。

研究设计与样本

  • 多中心前瞻性试验纳入452例初诊1-3期、所有生物学亚型的乳腺癌患者,54例退出,398例纳入全分析。
  • 所有参与者影像学确认对NST部分或完全缓解,在指南推荐的乳腺手术前接受研究特异性影像引导VAB。
  • 主要终点为VAB确认pCR-B的假阴性率(FNR)。

主要发现

  • 影像引导VAB单独在208例女性中的37例未检出手术确认的残留肿瘤(FNR 17.8%,95%CI 12.8-23.7%)。
  • 37例假阴性中,12例(32.4%)仅为残留DCIS,20例(54.1%)为微小残留肿瘤(<5 mm),25例中19例(76.0%)浸润性癌细胞密度≤10%。
  • 37例中19例(51.4%)的假阴性结果可能可以避免。
  • 探索性分析显示,使用最大体积针具(7-gauge)进行VAB无假阴性结果。
  • 将影像与影像引导VAB结合为单一诊断测试,FNR降至6.2%(95%CI 3.4%-10.5%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B). SUMMARY BACKGROUND DATA: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in up to 80% of women with breast cancer. In such cases, breast surgery, the gold standard for confirming pCR-B, may be considered overtreatment. METHODS: This multicenter, prospective trial enrolled 452 women presenting with initial stage 1-3 breast cancer of all biological subtypes. Fifty-four women dropped out; 398 were included in the full analysis. All participants had an imaging-confirmed partial or complete response to NST and underwent study-specific image-guided VAB before guideline-adherent breast surgery. The primary endpoint was the false-negative rate (FNR) of VAB-confirmed pCR-B. RESULTS: Image-guided VAB alone did not detect surgically confirmed residual tumor in 37 of 208 women [FNR, 17.8%; 95% confidence interval (CI), 12.8-23.7%]. Of these 37 women, 12 (32.4%) had residual DCIS only, 20 (54.1%) had minimal residual tumor (<5 mm), and 19 of 25 (76.0%) exhibited invasive cancer cellularity of ≤10%. In 19 of the 37 cases (51.4%), the false-negative result was potentially avoidable. Exploratory analysis showed that performing VAB with the largest needle by volume (7-gauge) resulted in no false-negative results and that combining imaging and image-guided VAB into a single diagnostic test lowered the FNR to 6.2% (95% CI, 3.4%-10.5%). CONCLUSIONS: Image-guided VAB missed residual disease more often than expected. Refinements in procedure and patient selection seem possible and necessary before omitting breast surgery.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Heil J, Pfob A, Sinn HP, et al. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. Ann Surg. 2022. PMID: 32657944. doi:10.1097/SLA.0000000000004246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。